The Food and Drug Administration (FDA) has approved Jadenu (deferasirox) for the treatment of chronic iron overload, a condition that can affect patients with myelodysplastic syndromes (MDS), sickle cell disease and thalassemia.
The FDA has updated the label for Zytiga plus prednisone to include data that detailed a significant prolongation in overall survival for Zytiga versus placebo in chemotherapy-naive men with metastatic castration-resistant prostate cancer.
The reason breathing techniques are so powerful, is they can lower blood pressure, heart rate and ease tension on capillaries.
Treatment with Avastin plus chemotherapy resulted in an improvement in overall survival of nearly five months compared with chemotherapy alone for women with platinum-sensitive recurrent ovarian cancer.
Treatment with the immunotherapy Vigil delayed time to progression in all patients with stage 3/4 ovarian cancer who were treated with the autologous tumor cell vaccine compared with those who were not, according to an open-label phase 2 trial.
Stomach cancer non-profit organization hosts "Hereditary Diffuse Gastric Cancer: The past, the present, and hope for the future" event.
Diet is precisely where we have the opportunity to provide our bodies with cellular mediators of inflammation.
Cancer is a lonely, confusing experience. Finding others who have walked the path before can be an emotional lifesaver.
Three-time cancer survivor tells about her experience with second opinions.
Jean M. Weigert, head of breast imaging for the Hospital of Central Connecticut, discusses results of a study examining supplemental ultrasound screening in women with dense breast tissue.
Melissa Long knows first-hand what it is like to battle isolation and depression as a teenage cancer survivor.
Oncologist Don Dizon explains the advantages of intraperitoneal therapy and why further research and education are necessary to bring it to the forefront of ovarian cancer treatment.
Elizabeth A. Mittendorf, associate professor of surgical oncology at The University of Texas MD Anderson Cancer Center, discusses the progress and potential of immunotherapy in breast cancer treatment.
The development of agents targeting the PD-1 immune checkpoint in the treatment of patients with advanced melanoma is progressing rapidly.
A trial comparing frontline Keytruda (pembrolizumab) with Yervoy (ipilimumab) for the treatment of advanced melanoma has met its progression-free survival and overall survival endpoints.
Anger is a common emotional response to being diagnosed with and treated for cancer. Openly expressing it can be a struggle.
Two years ago, Angelina Jolie Pitt told the world that she held the BRCA1 mutation.
A new study has found that a psychosocial telephone counseling intervention helps improve mood and quality of life in cervical cancer survivors.
Recent advancements in the treatment of ovarian cancer, including surgical techniques, the approvals of Avastin and Lynparza, and intraperitoneal chemotherapy, have led the National Comprehensive Cancer Network to make changes to their clinical practice guidelines in its 20th annual edition.
Results of a follow up study have shown that when women were taught stress management techniques early in their breast cancer treatment, their mood and quality of life continued to improve up to 15 years later.
Breast cancer specialist Mark Pegram discusses recent breast cancer studies and what's to come for patients with HER2-positive breast cancer.
In the ring, it's not about whether you win or lose; it's about never staying down and never giving up.
Two studies investigating Xtandi in men with early-stage metastatic castration-resistant prostate cancer (mCRPC) further confirmed the overall survival (OS) and progression-free survival (PFS) benefit of the agent over placebo, according to two recent studies.
Surgical oncologist Kelly K. Hunt, of MD Anderson Cancer Center, discusses how breast cancer interventions have progressed in the adjuvant and neoadjuvant setting and the role of sentinel lymph node dissection in the neoadjuvant setting.
PCF's Challenge Awards advance immunotherapy and optimal treatments for lethal prostate cancer.
Leaving the hospital is a huge relief, but there's still lots of work to do.
When my doctor told me that I had stage 4, grade 3a follicular lymphoma, I thought that it was impossible: I had firmly put cancer in my rear view mirror seven years prior. Yet here I was, hearing for the word "cancer" for the second time by the age of 26.
First-line treatment with Tykerb and a taxane failed to improve progression-free survival versus Herceptin plus a taxane in patients with HER2-positive metastatic breast cancer.
Saying goodbye to a friend in the middle of a shared cancer diagnosis can challenge the soul.
The PCF announced six new Challenge Awards to advance the treatment of lethal prostate cancer.
